Overview
Overview
Vilon (Lys‑Glu) is a synthetic immunoregulatory dipeptide consisting of lysine and glutamic acid residues[1]. Preclinical research indicates it may enhance immune markers including CD5+ lymphocytes and interleukin‑2 expression in thymic and splenic cell cultures[2][3]. This educational protocol presents a pulsed subcutaneous approach (5 consecutive days per 4‑week cycle) using a practical dilution for clear insulin‑syringe measurements. Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/m
- Category
- Longevity
- Routes
- subcutaneous
Mechanism
Vilon
Mechanism of action
Mechanism of action
Vilon belongs to a class of short bioregulatory peptides developed through Russian gerontology research [4] . In vitro studies demonstrate that the Lys‑Glu dipeptide can modulate lymphocyte populations and cytokine gene expression. Specifically, Vilon has been observed to increase CD5+ cell counts in thymus cell cultures [1] and upregulate interleukin‑2 (IL‑2) mRNA expression in splenocyte preparations [2] . Additional preclinical work suggests effects on TGF‑β1 and vascular permeability in renal models [3] . The pulsed 5‑day monthly regimen is analogized from related short peptide protocols such as Epitalon [5] .
Key research findings
- 01
Synthetic dipeptide (Lys-Glu, KE); one of the most-studied Khavinson short peptides, framed as a synthetic analog in the thymic/immune bioregulator line (related conceptually to thymalin/Thymogen).
- 02
In vitro: reported decondensation of heterochromatin and activation of previously silenced genes (including ribosomal genes) in cultured lymphocytes from older human donors - a central cell-culture finding behind the short-peptide epigenetic hypothesis.
- 03
Animal models (mouse/rat): studies from the originating group reported effects on immune markers and, in some experiments, on lifespan and spontaneous tumor incidence.
- 04
Human and independent data remain limited; most evidence is from a single research lineage.
Primary source: Vilon has more preclinical literature than most peptides in this series, including in-vitro chromatin studies in elderly-donor lymphocytes and rodent experiments. It nonetheless remains largely single-lineage and preclinical, with limited independent human evidence.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
Supports immune cell marker expression (CD5+ lymphocytes) and IL‑2 gene activity in cell culture models[1][2].
May modulate inflammatory cytokines such as TGF‑β1 under experimental renal stress conditions[3].
Early mouse studies suggest potential effects on tumor growth inhibition and lifespan extension, though human data remain limited[6].
Protocol Reference
Protocol reference
Commonly cited research range: 67–667 mcg, daily_for_cycles.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Cycle 1, Day 1
67 mcg (0.067 mg)
Cycle 1, Day 2
133 mcg (0.133 mg)
Cycle 1, Day 3
200 mcg (0.20 mg)
Cycle 1, Day 4
267 mcg (0.267 mg)
Cycle 1, Day 5
333 mcg (0.33 mg)
Cycle 2+ (Days 1–5)
333–667 mcg (0.33–0.67 mg)
| Phase | Reference amount | Units / volume |
|---|---|---|
| Cycle 1, Day 1 | 67 mcg (0.067 mg) | 1 unit (0.01 mL) |
| Cycle 1, Day 2 | 133 mcg (0.133 mg) | 2 units (0.02 mL) |
| Cycle 1, Day 3 | 200 mcg (0.20 mg) | 3 units (0.03 mL) |
| Cycle 1, Day 4 | 267 mcg (0.267 mg) | 4 units (0.04 mL) |
| Cycle 1, Day 5 | 333 mcg (0.33 mg) | 5 units (0.05 mL) |
| Cycle 2+ (Days 1–5) | 333–667 mcg (0.33–0.67 mg) | 5–10 units (0.05–0.10 mL) |
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 02🧴Inject slowly down the vial wall; avoid foaming.
- 03💉Gently swirl/roll until dissolved (do not shake).
- 04💧Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within ~1 week or aliquot and freeze[10].
- 05🔄Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) short‑term or −80 °C (−112 °F) long‑term in dry, dark conditions; minimize moisture exposure [10] .
Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~1 week or prepare aliquots and freeze to extend stability.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Clinical Evidence
Clinical evidence
Preclinical research reports immunomodulatory and geroprotective activity in animal and cell models.
Vilon has more preclinical literature than most peptides in this series, including in-vitro chromatin studies in elderly-donor lymphocytes and rodent experiments. It nonetheless remains largely single-lineage and preclinical, with limited independent human evidence.
- 01Synthetic dipeptide (Lys-Glu, KE); one of the most-studied Khavinson short peptides, framed as a synthetic analog in the thymic/immune bioregulator line (related conceptually to thymalin/Thymogen).
- 02In vitro: reported decondensation of heterochromatin and activation of previously silenced genes (including ribosomal genes) in cultured lymphocytes from older human donors - a central cell-culture finding behind the short-peptide epigenetic hypothesis.
- 03Animal models (mouse/rat): studies from the originating group reported effects on immune markers and, in some experiments, on lifespan and spontaneous tumor incidence.
- 04Human and independent data remain limited; most evidence is from a single research lineage.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to Vilon.
- 01Sevostianova NN et al. (2013) — Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells View Sourceet al. (2013)
- 02Kazakova TB et al. (2002) — In vitro effect of short peptides on expression of interleukin‑2 gene in splenocytes View Sourceet al. (2002)
- 03Gavrisheva NA et al. (2005) — Effect of Vilon peptide on TGF‑β1 and vascular permeability in chronic renal failure View Sourceet al. (2005)
- 04Kniaz’kin IA et al. (2002) — Effect of a peptide Vilon on immune aging (Adv Gerontol) View Sourceet al. (2002)
- 05Araj SK et al. (2025) — Overview of Epitalon—highly bioactive pineal tetrapeptide with promising properties (Int J Mol Sci) View Sourceet al. (2025)
- 06Chernyak EY et al. (2000) — Synthetic dipeptide Vilon inhibits tumor growth and prolongs life in mice (Dokl Biol Sci) View Sourceet al. (2000)
- 07Avolio F et al. (2022) — Peptides regulating proliferative activity and inflammatory pathways in THP‑1 macrophages (Int J Mol Sci) View Sourceet al. (2022)
- 08Wong AKC et al. (2024) — Injection techniques to reduce subcutaneous heparin complications (J Adv Nurs) View Sourceet al. (2024)
- 09MedlinePlus (NIH) — Subcutaneous (SQ) injections: patient information View Source
- 10Merck KGaA (Millipore Sigma) — Handling and storage guidelines for peptides and proteins View Source
- 11CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) View Source
- 12NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) View Source
- 13Pure Lab Peptides — Vilon (20 mg) product page (quality and batch documentation) View Source
Observed Effects
Observed effects in cited research
Reported
- Generally well tolerated in preclinical settings; occasional mild injection‑site reactions (redness/itch) may occur with subcutaneous administration.
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Current evidence is limited to in vitro and/or animal-model research; human data are minimal or absent. Consult a licensed healthcare professional for any clinical decisions.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| Vilonthis | A synthetic immunoregulatory dipeptide (Lys-Glu) studied for gene-regulatory and immunomodulatory activity, including effects on lymphocyte markers and chromatin structure. | subcutaneous | Investigational / RUO |
| Cartalax | A synthetic tripeptide bioregulator (Ala-Glu-Asp) studied for gene-regulatory activity in connective and cartilage tissue, with proposed anti-inflammatory and regenerative effects. | subcutaneous | Investigational / RUO |
| Chonluten | A short tripeptide bioregulator (Glu-Asp-Gly) studied for effects on bronchopulmonary tissue and modulation of inflammatory signaling in monocyte/macrophage models. | subcutaneous | Investigational / RUO |
| Cortagen | A synthetic tetrapeptide (Ala-Glu-Asp-Pro) of the Khavinson bioregulator class studied for neuroprotective and neuroregenerative activity, including peripheral nerve repair. | subcutaneous | Investigational / RUO |
| Epitalon (Epithalon) | A synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied for activation of telomerase and modulation of pineal/melatonin and circadian pathways, of interest in geroprotection research. | subcutaneous | Investigational / RUO |
| 5-Amino-1MQ | Inhibits nicotinamide N-methyltransferase (NNMT), increasing NAD+ availability and enhancing mitochondrial metabolism. | oral, subcutaneous | Investigational / RUO |
| Adipotide | A peptidomimetic that targets prohibitin on the vasculature of white adipose tissue and delivers a pro-apoptotic sequence, studied for selective reduction of fat-tissue blood supply. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
Vilon is a synthetic dipeptide with the sequence Lys-Glu (KE), one of the original short peptides in the Khavinson bioregulator series, framed in research as a thymic/immune-associated peptide. It is a Research Use Only material.
Cell-culture studies report chromatin decondensation and reactivation of silenced genes in lymphocytes from older donors, interpreted within the short-peptide bioregulator (epigenetic modulation) hypothesis. These are in vitro observations.
Most work is in vitro (human lymphocyte culture) and in rodent models from the originating group. Robust independent human trials are limited.
Store the lyophilized peptide desiccated and protected from light; refrigerate reconstituted solutions and follow the protocol reference and product documentation.
It is not an approved drug or consumer product. It is handled as Research Use Only and is not intended for human or veterinary use.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.